Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Single Center, Randomized, Open-label, 5-fold Crossover Study in Healthy Male Subjects to Investigate the Pharmacokinetic Dose Proportionality of BAY94-8862 Given as 5 Different Single Oral IR Tablet Doses (1.25, 2.5, 5.0, 7.5 and 10 mg)

This study should estimate the dose proportionality of BAY94-8862 IR tablets.

Inclusion Criteria:

• Healthy male subject
• Age: 18 to 46 years (inclusive) at the first screening examination
• Ethnicity: White
• Body mass index (BMI): >= 18 and <= 29.9 kg / m²

Exclusion Criteria:

• Clinically relevant findings in the ECG (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec
• Systolic blood pressure below 100 or above 140 mmHg
• Diastolic blood pressure below 50 or above 90 mmHg
• Heart rate below 50 or above 95 beats/ min
• Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2)
• Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)